My View on Team Building
Release time:
2020-07-15
This year, the overall working ideas and requirements of the management team in the raw material workshop of our pharmaceutical factory are summarized in four words: responsibility and efficiency. In the process of arranging work, managers should refine the division of labor and assign responsibilities to people; in the process of promoting work, they should emphasize the implementation of responsibilities and highlight work efficiency; when evaluating their own work and subordinates' work, they should focus on the effect of responsibility implementation and the improvement of work efficiency. Responsibility and efficiency are like a person's left hand and right hand, two hands are equally important, two hands are indispensable, both hands must be strong. For a long time to come, "responsibility" and "efficiency" will be a yardstick to measure our work. Especially when managers face problems, they should use this criterion to solve the problem.
At the same time, when promoting the management concepts of "responsibility" and "efficiency", managers should adhere to the result-oriented approach and achieve the "five priorities": emphasizing system implementation, responsibility implementation, supervision in place, rewards and punishments, and repeated summary learning to ensure that the management concepts of "responsibility" and "efficiency" are implemented, finally, a cultural atmosphere of implementing responsibilities and pursuing work efficiency is formed in the workshop.
As the director of the raw material workshop, I have four requirements for the management team:
The meeting will be fully discussed and not discussed in private. The members of the management team can speak freely at the closed-door meeting. Once a resolution is formed, members of the management team are not allowed to privately discuss and express opinions and opinions that are different from the resolution.
Communicate privately and avoid public kidnapping. It is normal for members of the management team to have different opinions or even differences at work. We can make up for differences and solve problems through private and frank communication, instead of blushing in public or attacking each other in WeChat groups. This is childish and stupid.
Communicate calmly and avoid yelling. The premise of communication is mutual respect, empathy, and peace of mind. The atmosphere of communication should also be friendly, honest with each other, open-minded, not yelling, let alone rage. As the saying goes: "reason is not loud." People who yell or get angry at things are not suitable for living in today's people-oriented society.
Mutual cooperation, mutual understanding and compromise. "The beginning of all things, the road to simple, derived to complex." Nowadays, the division of labor in society is becoming more and more detailed. No one knows everything, let alone everything. Therefore, in order to make up for the lack of individuals, there has been a team to work together. With a team, it is necessary to cooperate, cooperation will inevitably have different ideas and opinions, and even differences. When communication with each other is not enough to reach a consensus, the team must understand each other, reach a compromise, unite and move forward. (Liu Bin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31